Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results , but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q3 CY2025, with sales falling 3.8% year on year to $38.44 million. Its non-GAAP loss of $0.12 per share was 14.2% above analysts’ ...

MENLO PARK, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent first-quarter results, is expected to ...